Heart failure biomarker tests: common diagnostic traps
At standard acute-care rule-out thresholds, BNP below 100 ng/L has 95% sensitivity for acute heart failure; NT-proBNP below 300 ng/L has 99% sensitivity.
Those figures make natriuretic peptides useful when the clinical question is whether acute heart failure is unlikely. They do not make either result a stand-alone diagnosis.
Heart failure biomarker testing pitfalls begin when a concentration is read without the conditions that shaped it. Sacubitril/valsartan can raise BNP. Obesity can suppress it. Reduced renal clearance and atrial fibrillation can raise NT-proBNP and BNP. Each effect changes what a number means at the bedside.
Pharmacological confounder: the ARNI effect
Sacubitril/valsartan inhibits neprilysin, an enzyme that degrades BNP. During ARNI treatment, plasma BNP can rise because its breakdown is reduced. A result above the usual threshold may therefore reflect the drug’s effect on peptide handling rather than a new deterioration in cardiac filling pressures.
NT-proBNP follows a different clearance route. Neprilysin does not clear it, so ARNI therapy does not produce the same direct elevation. When a patient taking sacubitril/valsartan needs natriuretic peptide assessment, the distinction between the two assays matters.
That distinction has a practical limit. NT-proBNP is not immune to other confounders. Renal impairment and atrial fibrillation can raise it independently. A value still needs to be read against the patient’s rhythm, renal function, symptoms, examination and imaging.
The common diagnostic error is to treat BNP and NT-proBNP as interchangeable labels for the same measurement. They are related biomarkers, but the assay choice changes how medication affects the result. Before interpreting a BNP increase in a patient on an ARNI, establish when therapy began and whether the patient’s clinical status changed at the same time. If symptoms, congestion or imaging are worsening, the biomarker is one input to the assessment. If the patient is clinically stable, an isolated BNP rise should not trigger a heart-failure escalation by itself.
In a patient taking sacubitril/valsartan, a BNP rise has a pharmacological explanation that must be tested before it is treated as a change in heart-failure status.
Do not use BNP as a simple response marker during active sacubitril/valsartan treatment. Its concentration may be altered by the drug’s mechanism. NT-proBNP avoids that specific neprilysin effect, but it still requires interpretation in context.
Obesity can suppress the signal
Obesity is associated with lower B-type natriuretic peptide concentrations. That creates a false-negative risk: a patient may have heart failure while BNP is lower than expected for the degree of disease. A low value in a severely obese patient therefore carries less reassurance than the same value in a patient without this suppression.
This issue is especially consequential when a clinician uses a threshold as a binary gate. If the assay result is below the cut point, the temptation is to stop the evaluation. That is unsafe when the clinical picture remains suggestive. Dyspnea, volume status, echocardiographic findings and the trajectory of symptoms still matter.
The biomarker does not measure congestion directly. It reflects peptide release and clearance, both of which vary across patients. In obesity, the release signal can be muted. The result may underestimate heart-failure severity rather than accurately exclude it.
A useful interpretation sequence is:
1. Check the pretest picture. Assess symptoms, signs of congestion, oxygenation and available imaging. A low peptide value should not overrule strong evidence of acute decompensation.
2. Identify factors that suppress or raise the result. Obesity can suppress BNP. Renal impairment, age and atrial fibrillation can raise natriuretic peptide concentrations.
3. Use the value for the question it can answer. Low results are most useful for making acute heart failure less likely when the clinical context supports that interpretation. Elevated values require an explanation.
4. Resolve discordance with clinical assessment and imaging. If the biomarker and the patient do not agree, investigate the mismatch rather than selecting whichever result is more convenient.
This is the central discipline in clinical interpretation of NT-proBNP levels as well. The assay is not a direct readout of left-ventricular function, and a low result is not an absolute exclusion in every phenotype. A discordant value is a prompt to check the conditions around the measurement.
Renal function and age shift the baseline
NT-proBNP is cleared primarily through the kidneys. Reduced renal function lowers clearance and raises circulating concentrations. Advanced age also reduces clearance and is associated with higher baseline levels. As a result, fixed cutoffs can produce false positive cardiac biomarker results when these factors are ignored.
An elevated NT-proBNP in chronic kidney disease does not establish acute heart failure. It may reflect impaired clearance, cardiac stress, or both. The same problem appears in older patients, whose baseline concentrations may differ from those of younger patients. The number needs to be interpreted alongside renal function, age, rhythm and the clinical presentation.
This does not make the assay useless in renal disease. It changes the weight assigned to the result. A markedly abnormal value in a patient with compatible symptoms may support the diagnosis, but an elevated result alone cannot identify the mechanism. The clinician still needs to determine whether there is new congestion or another cause of the biomarker signal.
Serial measurements can help when they answer a defined clinical question, but biological variation limits how much meaning to assign to small changes. NT-proBNP has intrinsic biological variability of about 25%. A modest movement may fall within expected variation, particularly if sampling conditions and clinical status are not comparable. BNP has greater reported biological variability, about 40%.
The practical approach is to document the conditions that make a comparison interpretable: assay type, timing, renal function, rhythm, medication exposure and whether the patient’s clinical state has changed. A trend without those details can create false precision.
Atrial fibrillation raises both biomarkers
Atrial fibrillation independently elevates BNP and NT-proBNP. In a patient presenting with an arrhythmia, an elevated peptide concentration may therefore reflect the rhythm as well as heart failure. The same interpretive problem can arise in patients undergoing hemodialysis, where renal clearance and volume shifts complicate the signal.
This is one reason a high result has less diagnostic specificity than a low result has rule-out value in acute care. At the standard thresholds, the sensitivity for excluding acute heart failure is high: 0.95 for BNP at 100 ng/L and 0.99 for NT-proBNP at 300 ng/L. The corresponding negative predictive values are 0.94 and 0.98. These values describe performance in the relevant acute-care setting; they do not mean that every patient below threshold is free of heart failure, or that every patient above it has heart failure.
When atrial fibrillation is present, ask whether the patient has evidence of congestion or structural cardiac disease beyond the peptide result. Review the ventricular rate and rhythm context, renal function, symptoms and echocardiography. If the patient is also receiving hemodialysis, interpret the concentration with attention to the timing of sampling relative to dialysis and the patient’s volume status. A single number cannot separate these influences.
Kinetics affect acute interpretation
BNP and NT-proBNP do not move through the circulation at the same rate. BNP has a half-life of roughly 20 minutes. NT-proBNP has a half-life of about 60 to 120 minutes. Their biological variability also differs: approximately 40% for BNP and 25% for NT-proBNP.
These differences matter when interpreting a sample taken during a changing clinical state. A short half-life does not make BNP a clean real-time gauge of cardiac function, especially when ARNI therapy alters its degradation. A longer half-life means NT-proBNP may not track an abrupt change on the same timescale as symptoms or treatment. Neither assay should be treated as a moment-by-moment pressure monitor.
For biomarker testing in acute heart failure, keep the purpose narrow. A low value can help reduce the probability of acute heart failure when the patient and test result are aligned. An elevated value contributes evidence, but it does not establish the diagnosis without clinical correlation. If the patient is deteriorating, do not wait for a biomarker trend to confirm what examination and imaging already show.
| Feature | BNP | NT-proBNP |
|---|---|---|
| Approximate plasma half-life | 20 minutes | 60–120 minutes |
| Approximate biological variability | 40% | 25% |
| Effect of sacubitril/valsartan | Can rise because neprilysin inhibition reduces degradation | Not directly affected by neprilysin |
| Important interpretive confounders | Obesity can suppress levels; atrial fibrillation can raise them | Renal impairment, advanced age and atrial fibrillation can raise levels |
| Acute-care rule-out threshold | 100 ng/L | 300 ng/L |
The thresholds in the table are rule-out thresholds for acute care, not universal diagnostic cutoffs. They should not be repurposed as stand-alone rule-in values or applied without regard to the population and clinical setting.
A focused troubleshooting route
When a natriuretic peptide result appears inconsistent with the presentation, work through the discrepancy in a fixed order:
1. Confirm the assay. Determine whether the result is BNP or NT-proBNP. Do not transfer a cutoff or medication interpretation from one assay to the other.
2. Check ARNI exposure. If the patient takes sacubitril/valsartan, account for the potential BNP elevation. NT-proBNP avoids this specific drug effect.
3. Review body habitus. Obesity can suppress BNP and lead to underestimation. A low value should not end the workup when the clinical evidence remains strong.
4. Review renal function and age. Reduced clearance in chronic kidney disease and advanced age can raise baseline concentrations, increasing false-positive interpretations if fixed cutoffs are used without context.
5. Check rhythm. Atrial fibrillation can elevate either biomarker independently.
6. Match the number to the clinical question. Use acute rule-out thresholds to lower the probability of acute heart failure, not to claim that a result alone proves or disproves every form of heart failure.
7. Use imaging and examination to resolve conflict. When symptoms, signs and the biomarker disagree, the next step is clinical reassessment, not blind repetition of the same test.
This sequence is particularly useful when a result will drive resource-intensive decisions, such as admission, diuresis or further imaging. It keeps the assay in its proper role: a probability-shifting measurement, not a substitute for diagnosis.